Systems and methods for treatment of disease via application of mechanical force by controlled rotation of nanoparticles inside cells

Patent metadata

Field	Value
Publication number	US-10912947-B2
Application number	US-201615255611-A
Country	US
Kind code	B2
Filing date	Sep 2, 2016
Priority date	Mar 4, 2014
Publication date	Feb 9, 2021
Grant date	Feb 9, 2021

Abstract

The present disclosure describes systems, apparatus, and methods for application of dynamic magnetic field (DMF) treatment to direct movement, and specifically rotation, of magnetic particles associated with a target structure, so that mechanical force is applied to the target structure. In certain embodiments, the present disclosure demonstrates application of DMF treatment to direct rotation about the axis in individual magnetic particles (e.g., superparamagnetic nanoparticles), effecting permeabilization and/or other disruption of membranes (e.g., cell membranes and/or intracellular membranes). In certain embodiments, the present disclosure describes use of an alternating current superconductor (ACSC) to greatly enhance the magnetic field amplitude so that the field can penetrate deeper into a body with sufficient amplitude to control movement of the nanoparticles within a working volume.

First claim

What is claimed is:

1. A method of applying mechanical force to a target structure, the method comprising:
exposing a target structure to magnetic particles so that the magnetic particles bind to the target structure; and
applying a dynamic magnetic field (DMF) with a strength of at least 30 mT to the magnetic particles to induce rotation of each of the magnetic particles about an axis of the magnetic particles, so that a mechanical force within the range of about 1 fN to about 1 nN is applied to the target structure, wherein the DMF is applied using a DMF generator, and the DMF generator comprises an actuator comprising an array of superconducting coil windings.

2. The method of claim 1 , wherein the mechanical force is applied to the target structure without the magnetic particles being significantly heated.

3. The method of claim 1 , wherein the magnetic particles are or comprise a member selected from the group consisting of nanoparticles, superparamagnetic nanoparticles, and superparamagnetic iron oxide nanoparticles (“SPIONs”).

4. The method of claim 1 , wherein the magnetic particles are characterized by an iron oxide core.

5. The method of claim 1 , wherein the magnetic particles are characterized in losing their magnetism when not exposed to an external magnetic field.

6. The method of claim 1 , wherein the magnetic particles are associated with a targeting agent that specifically binds to the target structure.

7. The method of claim 6 , wherein the targeting agent is covalently linked to the magnetic particles.

8. The method of claim 6 , wherein the targeting agent is or comprises a member selected from the group consisting of antibodies, polypeptides, small molecules, glycans, lipids, and nucleic acids that specifically bind to a target moiety in or on the target structure, and combinations thereof.

9. The method of claim 8 , wherein the target moiety is or comprises a member selected from the group consisting of polypeptides, glycans, and nucleic acids.

10. The method of claim 1 , wherein the target structure is or comprises a member selected from the group consisting of cell membranes, tumor-associated markers, ion channels, intracellular membranes, lysosomal membranes, intracellular entities, and tumor-associated entities.

11. The method of claim 10 , wherein the intracellular entities are or comprise an organelle.

12. The method of claim 11 , wherein the organelle is selected from the group consisting of endoplasmic reticulum (ER), golgi apparatus, mitochondria, and combinations thereof.

13. The method of claim 10 , wherein the intracellular entities are or comprise a member selected from the group consisting of organelles, components of transcription machinery, splicosomes, and ribosomes.

14. The method of claim 10 , wherein the target structure is or comprises lysosomal membranes, and the magnetic particles are associated with a targeting agent that specifically binds to the target structure.

15. The method of claim 14 , wherein the targeting agent is covalently linked to the magnetic particles.

16. The method of claim 15 , wherein the targeting agent specifically binds to a target moiety on the surface of the lysosomal membrane.

17. The method of claim 16 , wherein the target moiety is or comprises LAMP-I (CD107a), LAMP-2 (CD107b), or LAMP-3 (CD63).

18. The method of claim 1 , wherein the step of exposing comprises exposing the target structure to the magnetic particles so that the magnetic particles bind to the target structure with a density sufficient to apply the mechanical force across a relevant area of the target structure.

19. The method of claim 10 , wherein the step of exposing comprises exposing the target structure to the magnetic particles so that, on average, about 1 to about 60 magnetic particles become bound to each lysosomal membrane.

20. The method of claim 19 , wherein the step of exposing comprises exposing the target structure to the magnetic particles so that, on average, about 10 to about 50 magnetic particles become bound to each lysosomal membrane.

21. The method of claim 19 , wherein the step of exposing comprises exposing the target structure to the magnetic particles so that, on average, about 30 magnetic particles become bound to each lysosomal membrane.

22. The method of claim 1 , wherein the strength is within the range of 30 mT to 5 T.

23. The method of claim 1 , wherein the applying step comprises applying the dynamic magnetic field with an in vivo reach selected from the group consisting of within the range of at least 1 cm, of at least 2 cm to 5 cm, of at least 10 cm, and of at least 50 cm.

24. The method of claim 10 , wherein the tumor-associated markers are or comprise a member selected from the group consisting of cell-surface entities and intracellular entities.

25. The method of claim 1 , wherein the applying step comprises controlling a rotation speed of each of the magnetic particles.

Assignees

• Memorial Sloan Kettering Cancer Center

Inventors

• Kircher Moritz F
• Renström Erik
• Koch Martin
• Stetter Ernst
• Reis Thomas

Classifications

• A61K41/0028 Primary

  Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds · CPC title

• A61K47/6849

  the antibody targeting a receptor, a cell surface antigen or a cell surface determinant · CPC title

• A61N2/02 Primary

  using magnetic fields produced by coils, including single turn loops or electromagnets (A61N2/12 takes precedence) · CPC title